The Southeast BIO Investor and Partnering Forum in partnership with the University of Florida’s Commercialization Program are pleased to bring you a Biotech/Pharma Breakfast on November 15, 2017 focusing on Regenerative Medicine. Throughout history, medical experts have dreamed of healing untreatable wounds, replacing a disfiguring scar with healthy skin, growing replacement lungs in the laboratory, and replacing a leg lost to injury or disease. Today, regenerative medicine has the potential to heal damaged tissues and organs, offering hope for those who have lost organ function due to age, disease, or injuries. This panel will include Dr. Anthony Atala, Dr. David Ayares, and Dr. Robert Guldberg. Brent Bellows will lead the discussion.
Anthony Atala asks, “Can we grow organs instead of transplanting them?” His lab at the Wake Forest Institute for Regenerative Medicine is doing just that — engineering over 30 tissues and whole organs. Anthony Atala is the director of the Wake Forest Institute for Regenerative Medicine, where his work focuses on growing and regenerating tissues and organs. His team engineered the first lab-grown organ to be implanted into a human — a bladder — and is developing experimental fabrication technology that can “print” human tissue on demand. In 2007, Atala and a team of Harvard University researchers showed that stem cells can be harvested from the amniotic fluid of pregnant women. This and other breakthroughs in the development of smart bio-materials and tissue fabrication technology promises to revolutionize the practice of medicine.
Dr. Robert E. Guldberg holds the Parker H. Petit Director’s Chair in Bioengineering and Bioscience. In addition to his primary appointment in the Woodruff School of Mechanical Engineering, he is a program faculty member in the Georgia Tech/Emory Department of Biomedical Engineering. Dr. Guldberg’s research interests focus on musculoskeletal growth and development, functional regeneration following traumatic injury, and degenerative diseases, including skeletal fragility and osteoarthritis.
Revivicor is delivering the technology and promise of regenerative medicine. Revivicor’s vision is to provide a superior-quality, high volume, alternative tissue source as a solution for the critical shortage of human-compatible donor tissues, cells and organs. Dr. David L. Ayares, Ph. D. co-founded Revivicor Inc. in 2003 and serves as its Chief Executive Officer and Chief Scientific Officer. Prior to Revivicor, he served as the Chief Operating Officer and Vice President of Research and Development of PPL Therapeutics Inc. Prior to PPL, Dr. Ayares served 8 years in scientific management in the pharmaceutical industry, specifically Abbott Laboratories and Baxter Healthcare, working on cell therapies for diabetes, gene therapy of cancer and gene targeting in transgenic animal systems.
Brent R. Bellows, Ph.D. is a partner with Knowles Intellectual Property Intellectual Strategies (KIPS) in Atlanta, Georgia. Dr. Bellows focuses on pharmaceutical and biotechnology patent strategy, which includes prosecution, portfolio creation and management, litigation, product clearance, and freedom to operate including competitor analyses. Dr. Bellows is also immediate past Chair of the IP Section of the Georgia State Bar, with a membership of over twelve hundred IP lawyers. In this capacity, Dr. Bellows led the organization of educational programs, and was the official representative for the State Bar of Georgia for communications with IP Bars and organizations throughout the country. He has been named a “Rising Star” by Super Lawyer and one of Georgia’s “Legal Elite” by Georgia Trend Magazine in the are of Intellectual Property Law.